Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncology

npj Breast Cancer 2026 Open access

Read full text
Authors: G Grazia, Rodrigo Sánchez-Bayona, Casals-Pascual Climent, Tomás Pascual, Daniele Generali, Alessandra Gennari, Paolo Vigneri, Nadia Harbeck, Javier Cortés, A. Prat, F. Schettini
DOI: 10.1038/s41523-026-00904-5
Cited by: 8
References: 57

Abstract

Hormone receptor-positive/HER2-negative breast cancer evolves in response to therapy, demanding smarter, adaptive biomarker-based treatment strategies. We review emerging dynamic biomarkers to guide therapeutic decision-making, spanning tissue and liquid biopsies, metabolic imaging, and microbiome profiling, that capture tumor or host-related changes over time. By contrasting Academic and Industry approaches, we advocate for a cultural shift in clinical trial design and implementation, aiming to move from reactive to proactive Oncology.

Fields of Study & Subjects

HER2/EGFR in Cancer Research Breast Cancer Treatment Studies Advanced Breast Cancer Therapies

Publication details

Journal / source
npj Breast Cancer
Publisher
Springer Science and Business Media LLC
Volume
12
Issue
1
Publication date
28 January 2026
Language
EN